Home/Rare Diseases/Batten Disease

Neurological & Neuromuscular

Batten Disease

Also called Neuronal Ceroid Lipofuscinosis, NCL, juvenile neuronal ceroid lipofuscinosis

Batten disease encompasses a group of rare lysosomal storage disorders caused by mutations in genes affecting cellular waste disposal (particularly CLN genes), leading to accumulation of lipofuscin (age pigment) in neurons and other cells. The juvenile-onset form is most common, typically presenting ages 4-8 with progressive vision loss due to retinal degeneration, often beginning with night blindness.

...active trials

Live from ClinicalTrials.gov

View trials below

About trials for Batten Disease

Gene therapy for Batten disease (CLN2) has FDA approval for intracerebroventricular infusion in early-stage juvenile neuronal ceroid lipofuscinosis. Other clinical trials are evaluating gene therapy for other Batten disease subtypes.

Try Match Me →

About Batten Disease

Batten disease encompasses a group of rare lysosomal storage disorders caused by mutations in genes affecting cellular waste disposal (particularly CLN genes), leading to accumulation of lipofuscin (age pigment) in neurons and other cells. The juvenile-onset form is most common, typically presenting ages 4-8 with progressive vision loss due to retinal degeneration, often beginning with night blindness. Seizures develop in the first few years after symptom onset, initially focal but often progressing to generalized and drug-resistant seizures. Cognitive decline, behavioral changes, sleep disturbances, and progressive movement disorders (ataxia, dystonia, parkinsonism) follow. The disease progresses relentlessly, with death typically occurring in adolescence or early adulthood. Different genetic forms have variable progression rates.

Common Symptoms

  • Progressive vision loss starting with night blindness
  • Blindness usually by teenage years
  • Seizures, often progressive and drug-resistant
  • Cognitive decline and behavioral changes
  • Movement problems, ataxia, and dystonia
  • Sleep disturbances and progressive neurodegeneration

Who It Affects

Juvenile-onset form (most common) typically presents ages 4-8 with vision loss, progressing to seizures and cognitive decline. Other forms present at different ages. Affects males and females equally.

Getting Involved in Clinical Trials

Gene therapy for Batten disease (CLN2) has FDA approval for intracerebroventricular infusion in early-stage juvenile neuronal ceroid lipofuscinosis. Other clinical trials are evaluating gene therapy for other Batten disease subtypes. Early diagnosis through genetic testing is critical, as gene therapy benefits are greater with earlier treatment before extensive neuronal damage. The Batten Disease Support and Research Association provides comprehensive trial information and patient support. If Batten disease is diagnosed, discuss with your neurologist about gene therapy eligibility and timing of treatment initiation.

Trusted Sources

Active Clinical Trials for Batten Disease

Finding trials for Batten Disease...

Related Neurological & Neuromuscular Conditions

Neurological & Neuromuscular

Duchenne Muscular Dystrophy

Duchenne muscular dystrophy is an X-linked genetic disorder causing progressive muscle weakness and degeneration, beginn...

Neurological & Neuromuscular

Spinal Muscular Atrophy

Spinal muscular atrophy is an autosomal recessive genetic disorder affecting motor neurons in the spinal cord, causing p...

Neurological & Neuromuscular

Myasthenia Gravis

Myasthenia gravis is a chronic autoimmune neuromuscular disorder causing muscle weakness and rapid fatigue. Antibodies a...